Porownywarka

Crystagen vs Chonluten side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

CrystagenChonluten

Udostępnij porównanie peptydów

Wlasciwosc	Crystagen	Chonluten
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Glu-Asp-Pro, EDP	Glu-Asp-Gly, EDG
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical research; reported as supplement-approved in Russia Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; reported supplement approval in Russia; not FDA or EMA approved Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Immune system, spleen health, immune aging	Respiratory health, lung function, bronchial support
Jak dziala	Crystagen is presented as a cytogen-class short peptide. In the supplied source, the Khavinson group hypothesizes that EDP can influence lymphocyte proliferation and differentiation and may reactivate chromatin in aged immune cells, potentially relating to T-cell function through tissue-specific gene-expression regulation. The source explicitly treats this as a proposed epigenetic model supported by that group's in vitro work, not as independent scientific consensus.	Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.
Typowe dawkowanie	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily
Dawkowanie z badań	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typowy czas trwania	10-30 day cycles	10-30 day cycles
Podanie	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well tolerated (Reported by the source; detailed safety data are limited.) Limited safety data outside Russia (The source flags this as a limitation of the available safety evidence.) Not FDA approved (This is regulatory status rather than a physiological adverse effect.)	Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.) Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.) Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)
Podsumowanie researchu	The supplied source characterizes the published evidence as mainly in vitro and ex vivo. It notes work on EDP-class peptides in PHA-stimulated lymphocytes from elderly donors, including reported chromatin-structure changes, and mentions lymphocyte activity findings in thymic explant and epithelial-cell models. A Russian clinical-observational report is described as commonly cited, but the source says it was not a registered randomized trial, so human efficacy should be treated as preliminary.	The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.
Referencje	PubMed PMC +1 więcej International Journal of Molecular SciencesTransport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Crystagen

Chonluten

Kategoria

Bioregulatory

Znany tez jako

Glu-Asp-Pro, EDP

Glu-Asp-Gly, EDG

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical research; reported as supplement-approved in Russia

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; reported supplement approval in Russia; not FDA or EMA approved

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Immune system, spleen health, immune aging

Respiratory health, lung function, bronchial support

Jak dziala

Crystagen is presented as a cytogen-class short peptide. In the supplied source, the Khavinson group hypothesizes that EDP can influence lymphocyte proliferation and differentiation and may reactivate chromatin in aged immune cells, potentially relating to T-cell function through tissue-specific gene-expression regulation. The source explicitly treats this as a proposed epigenetic model supported by that group's in vitro work, not as independent scientific consensus.

Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.

Typowe dawkowanie

10-20 mg daily · Once or twice daily

Dawkowanie z badań

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typowy czas trwania

10-30 day cycles

Podanie

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Generally well tolerated (Reported by the source; detailed safety data are limited.)
Limited safety data outside Russia (The source flags this as a limitation of the available safety evidence.)
Not FDA approved (This is regulatory status rather than a physiological adverse effect.)

Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.)
Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.)
Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)

Podsumowanie researchu

The supplied source characterizes the published evidence as mainly in vitro and ex vivo. It notes work on EDP-class peptides in PHA-stimulated lymphocytes from elderly donors, including reported chromatin-structure changes, and mentions lymphocyte activity findings in thymic explant and epithelial-cell models. A Russian clinical-observational report is described as commonly cited, but the source says it was not a registered randomized trial, so human efficacy should be treated as preliminary.

The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.

Referencje

PubMed PMC

+1 więcej

International Journal of Molecular SciencesTransport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły